MedDataX Logo

Olpasiran Expanded Access Program

NCT ID: NCT07079267

Last Updated: 2025-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303

Atherosclerotic Cardiovascular Disease
ACTIVE_NOT_RECRUITING PHASE3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012

Cardiovascular Disease
RECRUITING PHASE3

Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients

NCT04269863

Peripheral Arterial Disease
UNKNOWN NA

Mobilization of Endothelial Progenitor Cells and Aspirin

NCT02674958

Hypertrophic Obstructive Cardiomyopathy
TERMINATED PHASE3

Optimum Platelet Inhibition After Coronary Bypass Surgery

NCT00262275

Ischemic Heart Disease
COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olpasiran

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amgen Call Center

Role: CONTACT

[email protected]
866-572-6436

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Olpasiran Expanded Access

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.
NCT01374698 COMPLETED PHASE4
Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)
NCT00981032 COMPLETED NA
Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study
NCT00330772 COMPLETED PHASE3
Women With Chest Pain and Normal Coronary Arteries Study
NCT00743197 TERMINATED NA
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
NCT07214857 COMPLETED
Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum
NCT03603366 COMPLETED
A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)
NCT07012629 RECRUITING PHASE3
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
NCT01360047 COMPLETED
Japanese Primary Prevention Project With Aspirin
NCT00225849 UNKNOWN PHASE4
Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy
NCT04059679 UNKNOWN PHASE4
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
NCT01360073 COMPLETED
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
NCT02548650 COMPLETED PHASE4
Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
NCT05308030 UNKNOWN EARLY_PHASE1
Aspirin Resistance Following Coronary Bypass Surgery
NCT00260377 TERMINATED NA
Rivaroxaban or Aspirin for Biological Aortic Prosthesis
NCT02974920 UNKNOWN PHASE4
WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
NCT04990791 COMPLETED PHASE4
Lovenox With Aspirin in Thawed Blastocyst Transfer
NCT06133803 RECRUITING PHASE4
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
NCT06280976 WITHDRAWN PHASE4
Aspirin and Plavix Following Coronary Artery Bypass Grafting
NCT01158703 TERMINATED PHASE4
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
NCT04324463 COMPLETED PHASE3
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
NCT00249873 COMPLETED PHASE3
Perioperative Aspirin Response in Patients Undergoing Vascular Surgery
NCT03587324 COMPLETED NA
Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up
NCT04371289 COMPLETED
Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty
NCT00289601 TERMINATED PHASE4
DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
NCT04218656 COMPLETED PHASE4